Stockscreener 앱 받기
131.27
4.21%
5.30
시간 외 거래:
130.95
-0.32
-0.24%
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says - Law360
Gilead Sciences highlights its antiviral portfolio as a long-term growth driver - AD HOC NEWS
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168 - Moomoo
Gilead Sciences consensus picture, shares steady on NASDAQ - AD HOC NEWS
Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - WSJ
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector - ChartMill
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell Top 200 Growth Benchmark - marketscreener.com
Gilead Sciences wins Trodelvy approvals, shares supported by oncology focus - AD HOC NEWS
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Dynamic Index - marketscreener.com
Gilead Sciences launches Trodelvy in TNBC, shares hold near $128 - AD HOC NEWS
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC - Insider Monkey
Price to sales forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences Raises Guidance After Results Top Views - WSJ
Enterprise value to revenue forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences clears a fresh 12?month high, shares react to new FDA approval - AD HOC NEWS
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative? - Yahoo Finance
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe - Yahoo Finance
GILD News | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Price to book forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Price to earnings forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences Inc (GILD) Shares Surge 3.3% -- What GF Score of 75 Tells Investors - GuruFocus
Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Gilead Sciences, Inc. Actuals & Estimates (VIE:GILD) - TradingView
Gilead Sciences, Inc. Actuals & Estimates (LSX:885823) - TradingView
Gilead Sciences, Inc. Actuals & Estimates (NASDAQ:GILD) - TradingView
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results - Insider Monkey
Gilead Sciences consensus stays robust, analysts stick to Moderate Buy rating - AD HOC NEWS
Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh - TradingView
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know - sharewise.com
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Benzinga
Could Chemotherapy Soon Be Optional? AstraZeneca and Gilead Drugs Show Promise for Breast Cancer Patients - Health and Me
Gilead Sciences updates oncology pipeline, shares steady on NASDAQ - AD HOC NEWS
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use - Yahoo Finance
Gilead Sciences secures key FDA cancer approval, shares trade near recent highs - AD HOC NEWS
Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer - BioSpace
Photo gallery, Gilead Sciences v Pain Relief Rx et al - Partnership for Safe Medicines
OP Asset Management Ltd Acquires Shares of 256,653 Gilead Sciences, Inc. $GILD - MarketBeat
New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer - MedCity News
Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer - marketscreener.com
GILD Receives FDA Approval for Trodelvy in Triple-Negative Breas - GuruFocus
FDA approves Gilead’s Trodelvy for first-line breast cancer By Investing.com - Investing.com Canada
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer - Gilead Sciences
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC - Yahoo Finance Singapore
Astellas Padcev and Gilead's Trodelvy grab key EU approvals - pharmaphorum
5 Set-It-and-Forget-It Stocks to Buy Right Now - Insider Monkey
Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Trade Ideas — BCBA:GILD.CI - TradingView
Gilead Sciences highlights ongoing commitment to Pride, inclusion in community and workplace - ABC7 Bay Area
Gilead receives EU nod for Trodelvy in first-line metastatic triple-negative breast cancer - grafa.com
EC approves Trodelvy as a first-line treatment for TNBC - The Pharma Letter
GILD Gains EU Approval for Trodelvy in Treating Triple-Negative Breast Cancer - GuruFocus
Gilead Sciences: The Market Is Underestimating Its Growth Runway (NASDAQ:GILD) - Seeking Alpha
Gilead’s Trodelvy wins EU approval for first-line breast cancer - Investing.com
Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment - marketscreener.com
Gilead’s Trodelvy wins EU approval for first-line breast cancer By Investing.com - Investing.com Canada
as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors - Business Wire
Gilead Sciences draws Cantor support, shares sit below $155 target - AD HOC NEWS
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks - Investing.com UK
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 - Investing.com UK
Gilead Sciences wins FDA backing for weekly HIV pill, Cantor sticks to Overweight call on the shares - AD HOC NEWS
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Moomoo
Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver? - Insider Monkey
Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 By Investing.com - Investing.com Canada
1.84%
자본화:
|
볼륨(24시간):